Article Text

PDF
AB0509 Deep Vein Thrombosis in Patients with Antiphospholipidic Syndrome and Lupus: the Role of Systemic Inflammation
  1. S. Caraiola1,
  2. C. Jurcut2,
  3. D. Nitescu3,
  4. A. Nicolau3,
  5. R. Jurcut1,
  6. A. Baicus1,
  7. C. Baicus1,
  8. C. Tanasescu1
  1. 1“Carol Davila” University of Medicine and Pharmacy
  2. 2“Dr. Carol Davila” Central University Emergency Military Hospital
  3. 3Colentina Clinical Hospital, Bucharest, Romania

Abstract

Background Antiphospholipid syndrome (APLS) is classically associated venous or arterial thrombotic events. However, the predictors for occurrence of deep vein thrombosis in patients with APLS and systemic lupus erythematosus (SLE) are incompletely evaluated.

Objectives The aim of this study was to evaluate the impact of systemic inflammation in patients with APLS secondary to SLE.

Methods In 47 patients with APLS secondary to SLE, we performed the evaluation of traditional risk factors associated with DVT. We assessed the inflammation parameters [erythrocyte sedimentation rate (ESR), fibrinogen and C-reactive protein (CRP) levels]. We divided the study group in two subgroups: A- patients with DVT; and B- patients without DVT or any other thrombotic event.

Results In our study group 18 (38.3%) patients were diagnosed with DVT. Mean age, sex distribution, smoking rate, obesity parameters (body mass index, abdominal circumference, wais-to-hip ratio) were similar in both subgroups. ESR (29.76±4.71 vs 19.71±2.63, p=0.05), fibrinogen (375.88±18.26 vs 326.71±12.45, p=0.02), CRP (12.09±3.68 vs 3.35±0.70, p=0.006) were found to have higher values in patients with DVT. However, in multivariate analysis, only CRP was independently associated with DVT (p=0.03).

Conclusions Inflammation seems to be one of the pathogenic pathways in patients with APLS secondary to SLE and DVT. Further studies are required in order to have valid conclusions.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.5743

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.